-

Cosette Pharmaceuticals Appoints Brad Leonard as Vice President, Generics Commercial Operation

Experienced commercial leader joins Cosette to drive the next phase of growth and transformation

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. In this role, Brad will spearhead Cosette’s generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets.

“Cosette is in the midst of an exciting period of accelerated growth and portfolio expansion, and Brad is the right commercial leader to take our business to the next level,” said Apurva Saraf, President and CEO, Cosette Pharmaceuticals. “Brad’s deep expertise in the pharmaceutical industry, combined with his track record of driving commercial success and fostering strategic partnerships, will be a catalyst for our continued momentum.”

Brad played a pivotal role in the growth and success of Upsher-Smith Laboratories, LLC using a customer-focused approach to enhance their financial performance and commercial presence - demonstrated by over eight HDMA Diana Awards for product excellence and overall company performance.

“I am honoured to join Cosette at this pivotal moment in its journey,” said Brad Leonard, Vice President, Generics Commercial Operations. “The company’s bold vision, entrepreneurial spirit, and relentless focus on innovation make this an incredibly exciting time to be part of the team. I look forward to collaborating with the talented individuals at Cosette to accelerate our commercial execution, expand our market reach, and set new standards of excellence for the customers and patients we serve.”

With 30+ years of experience in the pharmaceutical industry, Brad is an experienced pharmaceutical executive with a robust background in pharmaceutical access and patient delivery across both generic and branded markets, cultivating and sustaining strong customer relationships, developing award-winning commercialization teams, and consistently driving sales and profit growth.

Brad holds a B.S. in Business Administration & Management from the University of Minnesota.

About Cosette Pharmaceuticals:

Cosette Pharmaceuticals, Inc. (“Cosette”) is a US-based, fully integrated pharmaceutical company with a fast-growing portfolio of branded pharmaceuticals consisting of products in women’s health, cardiology and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (NASDAQ: HLNE). For more information, please visit www.cosettepharma.com and follow us on LinkedIn.

Contacts

Business Development: bd@cosettepharma.com
Commercial: sales@cosettepharma.com

COSETTE PHARMA

Details
Headquarters: Bridgewater, New Jersey, USA
CEO: Apurva Saraf
Employees: 350
Organization: PRI

Release Versions

Contacts

Business Development: bd@cosettepharma.com
Commercial: sales@cosettepharma.com

Social Media Profiles
More News From COSETTE PHARMA

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recomm...

Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations....

Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company, has completed the acquisition of Ambien® and Ambien CR® in the United States from Sanofi US. “We are excited at the addition of Ambien to our portfolio,” stated Apurva Saraf, President and CEO of Cosette. “We continue to leverage our demonstrated, best-in-class capabilities in executing complex carve-outs and integrating diverse products. This acquisition not only strength...
Back to Newsroom